Table 1.
HIV treatment pipeline 2003-2012.
| Class | Drug name | Generic name | Brand name | Sponsor | Status |
|---|---|---|---|---|---|
| NRTI | FTC | Emtricitabine | Emtriva | Triangle/Gilead | Approved (2003) |
| NRTI | AG1549 | Capravirine | Agouron/Pfizer | Discontinued (2005) | |
| NRTI | DAPD | Amdoxovir | Gilead/Emory/RFS Pharma | Discontinued (2010) | |
| NRTI | MIV-310, FLT | Alovudine | Boehringer Ingelheim/Medivir/Beijing Mefuvir | To Mefuvir (2008) | |
| NRTI | ACH-126443 | Elvudtabine | Achillion | Phase II (2007) | |
| NRTI | D-d4T, DPC-817 | Reverset | Pharmasset/Incyte | Discontinued (2006) | |
| NRTI | SPD-754, AVX-754, ATC | Apridtabine | Shire BioChem/Avexa | Discontinued (2010) | |
| NRTI | Racivir | Pharmasset | Discontinued (2008) | ||
| NRTI | 4’-Ed4T, OBP-601 (ex festinavir) | BMS-986001 | Bristol-Myers Squibb | Phase II (2012) | |
| NRTI | CMX-157 | Chimerix | Phase I (2012) | ||
| NtRTI | GS-7340, PMPA | Gilead | Phase II (2012) | ||
| NNRTI | TMC-125 | Etravirine | Intelence | Janssen (exTibotec) | Approved (2008) |
| NNRTI | Calanolide A | Advanced Life Sciences/Sarawak MediChem | Phase II (2005) | ||
| NNRTI | DPC-083.AI-183 | Bristol-Myers Squibb | Discontinued (2004) | ||
| NNRTI | TMC-278 | Rilpivirine | Edurant | Janssen (exTibotec) | Approved (2011) |
| NNRTI | BILR-355/r BS | Boehringer Ingelheim | Discontinued (2008) | ||
| NNRTI | UK-453061 | Lersivirine | Pfizer | Phase II (2012) | |
| NNRTI | Viramune XR | Boehringer Ingelheim | Approved (2011) | ||
| NNRTI injectable | Rilpivirine-LA | Janssen (exTibotec) | Phase I (2012) | ||
| PI | Atazanavir | Reyataz | Bristol-Myers Squibb | Approved (2003) | |
| PI | VX-175, GW-433908 | Fosamprenavir | Lexiva | Vertex/GlaxoSmithKline | Approved (2003) |
| PI | Tipranavir | Aptivus | Boehringer Ingelheim | Approved (2005) | |
| PI | TMC-114 | Darunavir | Prezista | Janssen (exTibotec) | Approved (2006) |
| PI | GSK-640385 | Brecanavir | GlaxoSmithKline | Discontinued (2007) | |
| PI | PPL-100 | Ambrillia/Merck | Discontinued (2008) | ||
| FI | T-20 | Enfuvirtide | Fuzeon | Trimeris/Hoffmann-La Roche | Approved (2003) |
| CCR5RI | SCH-C, SCH-351125 | Schering-Plough | Discontinued (2004) | ||
| CCR5RI | UK-427857 | Maraviroc | Selzentry | Pfizer | Approved (2007) |
| CCR5RI | SCD-D, SCH-417 | Vicriviroc | Schering-Plough | Discontinued (2010) | |
| CCR5RI/2RI | TAK-652, TBR-652 | Cenicriviroc | Takeda/Tobira | Phase II (2012) | |
| Inl | MK-0518 | Raltegravir | Isentress | Merck | Approved (2007) |
| Inl | GS-9137, JTK-303 | Elvitegravir | Gilead | Submitted (2012) | |
| Inl | S/GSK-1349572 | Dolutegravir | GlaxoSmithKline/ShionogiA’iiV | Phase III (2012) | |
| Inl | GSK-1265744 | GlaxoSmithKline/Shionogi | Phase II (2012) | ||
| Inl | GSK-1265744 (LA) | Long-acting GSK-1265744 | GlaxoSmithKline/Shionogi | Phase I (2012) | |
| Anti-CD4Mab | TNX-355, Hu5A8 | Ibalizumab | Tanox/Biogen Idec/TaiMed | Phase II (2011) | |
| AI | PRO-542 | Progenies | Discontinued (2004) | ||
| AI | PA-457, MPC-4326 | Bevirimat | Panacos/Vitex/Myriad | Discontinued (2011) | |
| AI | PRO-140 | Progenies | Discontinued (2011) | ||
| AI (g>120) | BMS-663068 | Bristol-Myers Squibb | Phase II (2012) | ||
| PK booster | GS-9350 | Cobidstat | Gilead | Submitted (2012) | |
| PK booster | SPI-251 | Sequoia | Discontinued (2011) | ||
| PK booster | CTP-518 | GlaxoSmithKline | On hold (2012) | ||
| FDC | ABC/3TC | Zidovudine/lamivudine | Epzicom | GlaxoSmithKline | Approved (2003) |
| FDC | FTCVTDF | Emtricitabine/te nofovir | Truvada | Gilead | Approved (2004) |
| FDC | EFV/FTC/TDF | Efavirenz/emtricitabine/ tenofovir |
Atripla | Bristol-Myers Squibb/Gilead | Approved (2006) |
| FDC | RLV/FTC/TDF | Rilpivirine/emtricabine/tenofovir | Complera/Eviplera | Janssen (ex Tibotec)/Gilead | Approved (2011) |
| FDC | EVG/COBI/FTC/TDF | Elvitegravir/cobicisat/ emtridtabine/tenofovir |
Quad | Gilead | Submitted (2012) |
| FDC | Elvitegravir/cobicistat/emtricitabine/GS-7340 | Gilead | Phase II (2012) | ||
| FDC | Darunavir/cobicistat/emtricitabine/GS-7340 | Janssen (ex Tibotec)/Gilead | Phase II (2012) | ||
| FDC | Dolutegravir/abacavir/lamivudine | 72-Trii | VilV | Phase III (2012) |
Adapted from Clayden et al., 2012 with permission.7 NRTI, nucleoside reverse transcriptase inhibitor; NtRTI, nucleotide reverse transcriptase inhibitor; NNRTI, non-nucleoside reverese transcriptase inhibitor; PI, protease inhibitor; FI, fusion inhibitor; CCR5RI, CCR5 receptor inhibitor; CCR2RI, CCR2 receptor inhibitor; InI, integrase inhibitor; AI, attachment inhibitor; MI, maturation inhibitor; PK booster, pharmacokinetic booster; FDC, fixed dose combination.